iNtRON, a bio-new drug developing venture company, has announced the completion of an efficacy evaluation study of BAL200. It has previously been awarded Orphan Drug Designation (ODD) by the FDA.
BAL200 is a novel bacteriophage-derived endolysin-based biologic for the treatment of ‘Inhalation Anthrax’. It provides a complete bactericidal activity, rapidly eradicating infected anthrax strains from the body.
